Skip to main content

Table 2 Progression free (PFS) and overall survival (OS)

From: SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

 

Arm A (N = 73)

Arm B (N = 74)

PFS

 Events, n (%)

49 (67.1 %)

54 (73.0 %)

 Censored, n (%)

24 (32.9 %)

20 (27.0 %)

 Median (95 % CI), months

10.3 (8.7, 11.4)

8.5 (6.5, 11.9)

 Log-rank test P-value

0.83

OS

 Events, n(%)

33 (45.2 %)

39 (52.7 %)

 Censored, n (%)

40 (54.8 %)

35 (47.3 %)

 Median (95 % CI), months

25.6 (18.9, NA)

18.7 (14.6, NA)

 Log-rank test P-value

0.24

  1. CI confidence interval